Cardiol Therapeutics Inc. CRDL.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.14% | 6.54% | -7.82% | -48.59% | -2.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.37% | 20.48% | -19.27% | -28.71% | -1.93% |
| Operating Income | -3.37% | -20.48% | 19.27% | 28.71% | 1.93% |
| Income Before Tax | 27.23% | -36.57% | 11.45% | 22.48% | -25.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.23% | -36.57% | 11.45% | 22.48% | -25.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.23% | -36.57% | 11.45% | 22.48% | -25.36% |
| EBIT | -3.37% | -20.48% | 19.27% | 28.71% | 1.93% |
| EBITDA | -3.57% | -20.70% | 19.11% | 27.75% | 1.47% |
| EPS Basic | 47.74% | -3.58% | 27.37% | 36.08% | -4.28% |
| Normalized Basic EPS | 47.70% | -3.43% | 27.31% | 36.05% | -4.34% |
| EPS Diluted | 47.74% | -3.58% | 27.37% | 36.08% | -4.28% |
| Normalized Diluted EPS | 47.70% | -3.43% | 27.31% | 36.05% | -4.34% |
| Average Basic Shares Outstanding | 39.06% | 31.93% | 21.81% | 21.31% | 20.22% |
| Average Diluted Shares Outstanding | 39.06% | 31.93% | 21.81% | 21.31% | 20.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |